Protagonist Therapeutics(NASDAQ) PTGX

Protagonist Therapeutics makes new medicines using special proteins. These treatments help people with blood disorders and immune problems. Patients can often take these drugs as pills or simple shots.

Peptides and Pills

• ICOTYDE: Oral peptide approved for moderate-to-severe plaque psoriasis in adults and children 12 years and older.
• Rusfertide: Injectable candidate for polycythemia vera, a rare blood disorder that causes too many red blood cells.
• Obesity Program: Pipeline of early-stage drugs designed to mimic hormones that control weight and improve metabolism.
• IL-17 Program: Experimental oral treatment for skin diseases like plaque psoriasis, psoriatic arthritis, and spondyloarthritis.

Strategic Partnerships and Progress

• Received regulatory approval for its first oral peptide treatment, ICOTYDE, in March 2026.
• Exercised an opt-out right for profit sharing with Takeda in April 2026 for a $200 million payment.
• Earned Breakthrough Therapy status for rusfertide in August 2025 to treat a rare blood disorder.
• Nominated two new experimental obesity treatments for development during 2025.

What Sets Protagonist Apart?

Protagonist uses an in-house discovery platform to create peptide medicines that target proven biological pathways. The company focuses on turning complex injectable treatments into oral pills to make managing chronic diseases easier for patients.

The Latest Financial Data

• License and collaboration revenue was $213.5 million for the three-month period ended June 30, 2026.
• Net income for the quarter ended June 30, 2026, was $162.8 million.
• Cash, cash equivalents, and marketable securities reached $849.5 million as of June 30, 2026.
• Research and development expenses were $42.1 million for the three-month period ended June 30, 2026.
• Earned a $50 million milestone payment in March 2026 following regulatory approval for its psoriasis treatment.

Bottom Line

Protagonist has evolved from a research firm to a commercial company through its partnership with Janssen. Its focus on turning complex biologics into oral pills allows it to address high-demand medical markets.